Table of Contents Author Guidelines Submit a Manuscript
Contrast Media & Molecular Imaging
Volume 2017, Article ID 3981358, 7 pages
https://doi.org/10.1155/2017/3981358
Research Article

Preliminary 19F-MRS Study of Tumor Cell Proliferation with 3′-deoxy-3′-fluorothymidine and Its Metabolite (FLT-MP)

1Division of RI-Convergence Research, Korea Institute of Radiological & Medical Sciences, Seoul, Republic of Korea
2Convergence Institute of Biomedical Engineering and Biomaterials, Seoul National University of Science & Technology, Seoul, Republic of Korea
3Division of Medical Radiation Equipment, Korea Institute of Radiological & Medical Sciences, Seoul, Republic of Korea
4Department of Chemical & Biomolecular Engineering, Seoul National University of Science & Technology, Seoul, Republic of Korea
5Department of Nuclear Medicine, Korea Institute of Radiological & Medical Sciences, Seoul, Republic of Korea

Correspondence should be addressed to Jung Young Kim; rk.er.smarik@mikyj and Ji-Ae Park; rk.er.smarik@krapj

Received 11 May 2017; Accepted 17 July 2017; Published 26 September 2017

Academic Editor: Giancarlo Pascali

Copyright © 2017 In Ok Ko et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

The thymidine analogue 3′-deoxy-3′-[18F]fluorothymidine, or [18F]fluorothymidine ([18F]FLT), is used to measure tumor cell proliferation with positron emission tomography (PET) imaging technology in nuclear medicine. FLT is phosphorylated by thymidine kinase 1 (TK1) and then trapped inside cells; it is not incorporated into DNA. Imaging with 18F-radiolabeled FLT is a noninvasive technique to visualize cellular proliferation in tumors. However, it is difficult to distinguish between [18F]FLT and its metabolites by PET imaging, and quantification has not been attempted using current imaging methods. In this study, we successfully acquired in vivo spectra of natural or nonradioactive 3′-deoxy-3′-fluorothymidine ([19F]FLT) and its monophosphate metabolite (FLT-MP) in a tumor xenograft mouse model using 9.4T magnetic resonance imaging (MRI). This preliminary result demonstrates that 19F magnetic resonance spectroscopy (MRS) with FLT is suitable for the in vivo assessment of tumor aggressiveness and for early prediction of treatment response.